According to Reuters, Tesaro (TSRO) seeking strategic alternatives

  • March 1, 2017

U.S. biopharmaceutical company Tesaro (TSRO) is discussing its options with investment banks after receiving acquisition interest from several drugmakers, according to people familiar with the matter.

Tesaro shares rose as much as 17 percent on the news and were up 11 percent at $180.50 in late morning trading in New York on Wednesday, giving the company a market capitalization of more than $9 billion. Tesaro went public in 2012 at $13.50 per share.